Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease

NCT06944522 is registered in ClinicalTrials.gov with BlueRock Therapeutics as lead sponsor.

NCT NCT06944522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06944522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease
Lead sponsor
BlueRock Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
June 17, 2025
Completion date
March 31, 2032
Enrollment
102 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

parkinsons disease (pd)